ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2018
The economic burden of diabetes to French national health insurance: a new cost-of-illness method based on a combined medicalized and incremental approach.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 58 citations in OpenAlex.
- Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: A Cluster Randomized Controlled Study.Advances in therapy · 2019Trial
- Inequalities in oral anticoagulant treatment patterns: a two-part model to estimate healthcare costs associated with atrial fibrillation.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Economic burden of type 2 diabetes management in France according to clinical characteristics.Diabetes, obesity & metabolism · 2026Article
- Ten-Year Trends in Healthcare Use and Costs for People Living with Diabetes in France: Results from the Epicodiab Study Based on National Claims Data.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Unequal nursing: the impact of China's public health insurance on nursing services for older adults.BMC nursing · 2025Article
- Economic impact of patients with medical evacuation in remote islands: a case study in Matsu Islands.Frontiers in public health · 2025Article
- Delay and Pay? Healthcare Costs Associated with Late Oral Anti-coagulant Prescribing in People with Atrial Fibrillation.PharmacoEconomics · 2024Article
- Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France.Journal of comparative effectiveness research · 2024Article
- A systematic review of the economic burden of diabetes mellitus: contrasting perspectives from high and low middle-income countries.Journal of pharmaceutical policy and practice · 2024Review
- How can we improve the care of patients with schizophrenia in the real-world? A population-based cohort study of 456,003 patients.Molecular psychiatry · 2023Article
- Descriptive study of a clinical and educational telemedicine intervention in patients with diabetes receiving glargine 300 U/ml (Toujeo) in Spain: results of the T-Coach programme.Drugs in context · 2023Article
- Assessing real-world effectiveness of therapies: what is the impact of incretin-based treatments on hospital use for patients with type 2 diabetes?Health economics review · 2022Article
- Delineating the Type 2 Diabetes Population in the Netherlands Using an All-Payer Claims Database: Specialist Care, Medication Utilization and Expenditures 2016-2018.PharmacoEconomics - open · 2022Article
- Machine learning versus regression modelling in predicting individual healthcare costs from a representative sample of the nationwide claims database in France.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Article
- Utilization and cost of drugs for diabetes and its comorbidities and complications in Kuwait.PloS one · 2022Article
- Impact of Policies in Nutrition and Physical Activity on Diabetes and Its Risk Factors in the 28 Member States of the European Union.Nutrients · 2021Article
- Cost-Utility of Acromegaly Pharmacological Treatments in a French Context.Frontiers in endocrinology · 2021Article
- Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review.ClinicoEconomics and outcomes research : CEOR · 2021Review
- Prescription of Physical Activity by General Practitioners in Type 2 Diabetes: Practice and Barriers in French Guiana.Frontiers in endocrinology · 2021Article
- Comparing health insurance data and health interview survey data for ascertaining chronic disease prevalence in Belgium.Archives of public health = Archives belges de sante publique · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A better understanding of the economic burden of diabetes constitutes a major public health challenge in order to design new ways to curb diabetes health care expenditure. The aim of this study was to develop a new cost-of-illness method in order to assess the specific and nonspecific costs of diabetes from a public payer perspective. Using medical and administrative data from the major French national health insurance system covering about 59 million individuals in 2012, we identified people with diabetes and then estimated the economic burden of diabetes. Various methods were used: (a) global cost of patients with diabetes, (b) cost of treatment directly related to diabetes (i.e., 'medicalized approach'), (c) incremental regression-based approach, (d) incremental matched-control approach, and (e) a novel combination of the 'medicalized approach' and the 'incremental matched-control' approach. We identified 3 million individuals with diabetes (5% of the population). The total expenditure of this population amounted to €19 billion, representing 15% of total expenditure reimbursed to the entire population. Of the total expenditure, €10 billion (52%) was considered to be attributable to diabetes care: €2.3 billion (23% of €10 billion) was directly attributable, and €7.7 billion was attributable to additional reimbursed expenditure indirectly related to diabetes (77%). Inpatient care represented the major part of the expenditure attributable to diabetes care (22%) together with drugs (20%) and medical auxiliaries (15%). Antidiabetic drugs represented an expenditure of about €1.1 billion, accounting for 49% of all diabetes-specific expenditure. This study shows the economic impact of the assumption concerning definition of costs on evaluation of the economic burden of diabetes. The proposed new cost-of-illness method provides specific insight for policy-makers to enhance diabetes management and assess the opportunity costs of diabetes complications' management programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.